After Tivantinib Phase III Flop, ArQule Shifts Focus To Earlier-Stage Assets
Executive Summary
ArQule devotes investor call about tivantinib failure in MET-high liver cancer to its other pipeline candidates, including the FGFR inhibitor ARQ 087, which will enter pivotal testing in intrahepatic cholangiocarcinoma, a rare type of liver cancer, this summer.
You may also be interested in...
Deal Watch: Fresenius Drops Bid For Akorn, Citing Data-Integrity Concerns
Janssen and Bristol team to develop next-generation oral anticoagulant, while UCB buys Proximagen's nasal spray candidate and Duke spinout focused on genomics.
Safety concerns raised for ArQule, Daiichi Sankyo's cancer drug
US biotech company ArQule said a monitoring committee raised concerns about dosing level and the safety of a liver cancer therapy the drug maker is testing with partner Daiichi Sankyo.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.